secwatch / observer
8-K filed February 6, 2025, 6:59 PM ET ticker RCUS CIK 0001724521
leadership confidence high sentiment neutral materiality 0.25

Arcus Biosciences appoints Dietmar Berger to board replacing Merdad Parsey

Arcus Biosciences, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dietmar Berger

Class II Director
RCUS · Arcus Biosciences, Inc.
Effective
2025-02-06
Filed
February 6, 2025, 6:59 PM ET
On February 6, 2025, the Board appointed Dietmar Berger M.D., Ph.D., as a Class II director to fill the vacancy left by Dr. Parsey's resignation.
Departed

Merdad Parsey

Director
RCUS · Arcus Biosciences, Inc.
Effective
2025-02-06
Successor
Dietmar Berger
Filed
February 6, 2025, 6:59 PM ET
On February 6, 2025, in connection with his departure from Gilead Sciences, Inc. (“Gilead”), Merdad Parsey, M.D., Ph.D., resigned as a member of Arcus Biosciences, Inc.’s (“Arcus”) Board of Directors (the “Board”), effective upon the appointment of Gilead’s new director designee pursuant to the Amended and Restated Investor Rights Agreement dated January 29, 2024 by and between Arcus and Gilead.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dietmar Berger was appointed as Class II Director at Arcus Biosciences, Inc..

Action
appointed
Role
Class II Director
Exact text from the filing
On February 6, 2025, the Board appointed Dietmar Berger M.D., Ph.D., as a Class II director to fill the vacancy left by Dr. Parsey's resignation.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.9

Merdad Parsey resigned as Director at Arcus Biosciences, Inc..

Action
resigned
Role
Director
Exact text from the filing
On February 6, 2025, in connection with his departure from Gilead Sciences, Inc. (“Gilead”), Merdad Parsey, M.D., Ph.D., resigned as a member of Arcus Biosciences, Inc.’s (“Arcus”) Board of Directors (the “Board”), effective upon the appointment of Gilead’s new director designee pursuant to the Amended and Restated Investor Rights Agreement dated January 29, 2024 by and between Arcus and Gilead.
View on SEC.gov

Arcus Biosciences, Inc. filing history →

Source: SEC EDGAR
accession 0001724521-25-000024
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.